MFG
EDSA icon

Merit Financial Group’s Edesa Biotech EDSA Stock Holding History

Merit Financial Group’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,916
Closed -$33K – 595
2022
Q2 		$33K Buy
+2,916
New +$43K ﹤0.01% 553

Other funds holding EDSA

CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Merit Financial Group's EDSA Position: Q3 2022 in Review

Merit Financial Group sold out of Edesa Biotech (EDSA) in Q3 2022, closing a stake of 2,916 shares — an estimated $33K sold.

Merit Financial Group first reported a position in EDSA in Q2 2022 and held it in 1 quarter. The position peaked at $33K in Q2 2022. 21 funds tracked by Wall St. Rank hold EDSA as of Q3 2022.

  • Merit Financial Group reported no remaining Edesa Biotech position as of Q3 2022 after selling out during the quarter.
  • Merit Financial Group sold 2,916 Edesa Biotech shares in Q3 2022, an estimated $33K.
  • Merit Financial Group first reported a position in Edesa Biotech in Q2 2022 and held it in 1 quarter.
  • Merit Financial Group's Edesa Biotech position peaked at $33K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Edesa Biotech as of Q3 2022.

Based on Merit Financial Group's 13F filing for Q3 2022, filed 31 Oct 2022.